4 th Heidelberg Myeloma Workshop

Größe: px
Ab Seite anzeigen:

Download "4 th Heidelberg Myeloma Workshop"

Transkript

1 4 th Heidelberg Myeloma Workshop Current status and developments in diagnosis and therapy of Multiple Myeloma Congress venue: Lecture hall, Klinik für Innere Medizin Universitätsklinikum Heidelberg Friday, April 26 th 2013 (Meeting language English) and Saturday, April 27 th 2013 (Meeting language German) Prof. Dr. med. Hartmut Goldschmidt PD Dr. med. Kai Neben Prof. Dr. med. Anthony D. Ho Prof. Dr. med. Dirk Jäger Prof. Dr. med. Christof von Kalle Prof. Dr. med. Otmar D. Wiestler UniversitätsKlinikum Heidelberg

2 4 th 4 th Heidelberg Myeloma Workshop Current status and and developments in in diagnosis and and therapy of of Multiple Myeloma Greeting Dear colleagues, we are glad to welcome you to the 4 th Heidelberg Myeloma Workshop. It continues the series of events on new developments of diagnosis and improved treatment strategies of Multiple Myeloma. Myeloma patients are benefiting from many fundamental innovations in diagnosis and therapy in recent years. High response rates by the combination of new drugs and blood stem cell transplantation prolong the disease-free period as well as the overall survival to more than ten years. Also the quality of life has increased for patients with Multiple Myeloma. Several new substances are already in Phase III trials. Studies on the intensification of the therapy and the results on how the depth of remission influences the overall survival, offer new chances to further prolong the life of the patients. A precise classification of the prognosis of different patient groups can be achieved by analysis of genetic changes and characteristic clinical and molecular markers. This allows a targeted and effective therapy. Methods of imaging and of molecular medicine will continuously extend and improve our understanding of the disease. These advances are only possible due to continuous medical research. The approved SFB Transregio 79 on the sites Gießen, Dresden and Heidelberg also contributes to the development of new bone substitutes and implant materials. We very much hope that the planned Myeloma Workshop in Heidelberg will inform you comprehensively about current results of research and the progress in the diagnosis and treatment of Multiple Myeloma. We are convinced that the scientific exchange will contribute to a more rapid translation of approaches from cancer research into patient care and that thereby the success of the therapy for patients with Myeloma will be improved. A warm welcome to Heidelberg! Prof. Dr. Hartmut Goldschmidt and PD Dr. Kai Neben Seite 2 Seite 3

3 Grußwort Sehr geehrte Kolleginnen und Kollegen, wir freuen uns sehr, Sie zum 4 th Heidelberg Myeloma Workshop begrüßen zu dürfen. Dieser setzt die Reihe von Veranstaltungen zu neuen Entwicklungen der Diagnostik und verbesserten Therapiestrategien beim Multiplen Myelom fort. Patienten mit Multiplem Myelom profitieren von vielfältigen grundlegenden Neuerungen in Diagnostik und Therapie der letzten Jahre. Hohe Ansprechraten durch die Kombination aus neuen Medikamenten und Blutstammzelltransplantation verlängern sowohl den krankheitsfreien Zeitraum, als auch das Gesamtüberleben auf über zehn Jahre. Auch die Lebensqualität der Patienten mit Multiplem Myelom ist gestiegen. Mehrere neue Wirkstoffe befinden sich bereits in Phase III Studien. Untersuchungen zur Therapieintensivierung und Ergebnisse darüber, wie die Tiefe der Remission das Gesamtüberleben beeinflussen, bieten neue Chancen, das Leben der Patienten weiter zu verlängern. Eine präzise Abgrenzung der Prognose von verschiedenen Patientengruppen kann über den Nachweis von genetischen Veränderungen und charakteristischen klinischen und molekularen Markern erfolgen und ermöglicht eine gezielte und effektivere Therapie für die Patienten. Richtungsweisend sind hier die Verfahren der Bildgebung und der molekularen Medizin zu nennen, welche unser Verständnis der Erkrankung kontinuierlich erweitern und verbessern. Nur durch stetige medizinische Forschung sind solche Fortschritte möglich. Dazu trägt auch der im Jahre 2010 an den Standorten Gießen, Dresden und Heidelberg bewilligte SFB Transregio 79 zur Entwicklung von neuen Knochenersatzstoffen und Implantatwerkstoffen bei. Wir hoffen sehr, dass Sie die geplante Veranstaltung umfassend über aktuelle Forschungsergebnisse und die Fortschritte in der Diagnostik und Behandlung des Multiplen Myeloms informieren wird. Wir sind davon überzeugt, dass der Austausch vor Ort dazu beiträgt, richtungsweisende Entwicklungen schneller in die klinische Anwendung zu überführen und dadurch die Therapieerfolge bei Myelompatienten zu verbessern. Herzlich willkommen in Heidelberg! Prof. Dr. Hartmut Goldschmidt und PD Dr. Kai Neben Seite 4 Seite 5

4 Friday, 26 th April 2013 Meeting Language English / Seminarsprache Englisch Lecture hall, Klinik für Innere Medizin, Universitätsklinikum Heidelberg Until 11:00 a.m. arrival 10:30 a.m. 11:00 a.m. Coffee and breakfast 10:30 a.m. 11:00 a.m. Registration 11:00 11:15 Welcome, Introduction 4 th Heidelberg Myeloma Workshop Hartmut Goldschmidt, Heidelberg Peter Dreger, Heidelberg Otmar D. Wiestler, Heidelberg CV Abstract Slides 11:15 11:45 Key note lecture Paul Richardson Introducing Paul Richardson (Peter Dreger) The emerging role of novel therapies in the management of Multiple Myeloma Paul Richardson, Boston 11:45 12:15 Key note lecture Gareth Morgan 16 Introducing Gareth Morgan (Hartmut Goldschmidt) Molecular development of Multiple Myeloma role of Cereblon Gareth Morgan, London 12:15 12:45 Key note lecture Richard Houlston 18 Introducing Richard Houlston (Kari Hemminki) Genome wide association studies (GWAS) and prediction of cancer Richard Houlston, London 12:45 1:45 Lunch 1:45 3:05 Session I Diagnosis, prognosis and biological background of Multiple Myeloma Chairmen: Dirk Hose, Heidelberg, Hervé Avet-Loiseau, Toulouse CV Abstract Slides 1:45 2:05 Role of new imaging techniques in diagnosing and staging of patients with Multiple Myeloma Stefan Delorme, Heidelberg Questions and answers 2:05 2:25 Role for genomics in Multiple Myeloma Hervé Avet-Loiseau, Toulouse Questions and answers 2:25 2:45 From myeloma precursor disease to Multiple Myeloma Maria-Victoria Mateos, Salamanca Questions and answers 2:45 3:05 Familial risks and germline genetics of Myeloma Kari Hemminki, Heidelberg Questions and answers 3:05 3:30 Coffee break 3:30 4:50 Session II Therapy of Multiple Myeloma - drugs and treatment strategies Chairmen: Nicolaus Kröger, Hamburg, Marc-Steffen Raab, Heidelberg CV Abstract Slides 3:30 3:50 Immunmodulatory drugs in the treatment of Multiple Myeloma: focus on maintenance treatment Philippe Moreau, Nantes Questions and answers 3:50 4:10 Bone targeting agents in the treatment of Multiple Myeloma 42 Gareth Morgan, London Questions and answers 4:10 4:30 Monoclonal antibody-based therapy as a new treatment strategy in Multiple Myeloma Sundar Jagannath, New York Questions and answers 4:30 4:50 Autologous stem cell transplantation in the era of new drugs Pieter Sonneveld, Rotterdam Questions and answers 4:50 5:30 Coffee break Seite 6 Seite 7

5 5:30 6:45 Session III Treatment paradigm of Multiple Myeloma Chairmen: Hartmut Goldschmidt, Heidelberg, Peter Dreger, Heidelberg CV Abstract Slides Samstag, 27. April 2013 Seminarsprache Deutsch / Meeting Language German Hörsaal, Klinik für Innere Medizin, Universitätsklinikum Heidelberg 5:30 5:40 Introduction: Cure or chronification? Hartmut Goldschmidt, Heidelberg 5:40 6:00 Pro Cure Nicolaus Kröger, Hamburg 8:30 9:30 Sitzung IV Neues aus den Studiengruppen Vorsitzende: Dirk Jäger, Heidelberg, Martin Kropff, Münster CV Abstract Slides 6:00 6:20 Pro Chronification Morie A. Gertz, Rochester :20 6:35 Debate All 6:35 6:45 Summary Hartmut Goldschmidt, Heidelberg 8:30 9:00 DSMM (Deutsche Studiengruppe Multiples Myelom) 62 Hermann Einsele, Würzburg Fragen zum Vortrag 9:00 9:30 GMMG (German-Speaking Myeloma Multicenter Group) Hartmut Goldschmidt, Heidelberg Fragen zum Vortrag 9:30 9:50 Kaffeepause 9:50 11:10 Sitzung V Myelomdiagnostik im Jahr 2013: Was sind Standards in Deutschland? Vorsitzende: Christof Scheid, Köln, Christof von Kalle, Heidelberg CV Abstract Slides 9:50 10:10 Bildgebung beim Multiplen Myelom Jens Hillengaß, Heidelberg Fragen zum Vortrag 10:10 10:30 Molekulare Diagnostik beim Multiplen Myelom Dirk Hose, Heidelberg Fragen zum Vortrag 10:30 10:50 Standards der Kontroll- und Verlaufsuntersuchungen beim Multiplen Myelom Christof Scheid, Köln Fragen zum Vortrag 10:50 11:10 Multiples Myelom Therapierealität in Deutschland Hartmut Goldschmidt, Heidelberg Fragen zum Vortrag 11:10 13:30 Mittagspause mit Lunchsession Seite 8 Seite 9

6 11:30 12:40 Lunch Session Scientific Workshop Werkstoffe für die Geweberegeneration im systemisch erkrankten Knochen (SFB Transregio 79) Vorsitzende: Dirk Hose, Heidelberg, Christian Heiß, Gießen 13:30 14:30 Sitzung VI Therapieempfehlungen bei Patienten mit Multiplem Myelom I Vorsitzende: Stefan Fuxius, Heidelberg, Igor Blau, Berlin 11:30 11:40 Einführung Hartmut Goldschmidt, Heidelberg CV Abstract Slides 11:40 12:00 Entwicklung von Knochenersatzstoffen für die Behandlung von benignen und malignen Knochendefekten Die klinische Sicht Christian Heiß, Gießen Fragen zum Vortrag 12:00 12:20 Entwicklung von Knochenersatzstoffen für die Behandlung von benignen und malignen Knochendefekten Die pathophysiologische Sicht Dirk Hose, Heidelberg Fragen zum Vortrag 12:20 12:40 Entwicklung von Knochenersatzstoffen für die Behandlung von benignen und malignen Knochendefekten Die materialwissenschaftliche Sicht Michael Gelinsky, Dresden Fragen zum Vortrag 13:30 13:50 Die Primärtherapie von Patienten mit Multiplem Myelom 96 Martin Kropff, Münster Fragen zum Vortrag CV Abstract Slides 13:50 14:10 Die Rezidivtherapie von Patienten mit Multiplem Myelom Kai Neben, Heidelberg Fragen zum Vortrag 14:10 14:30 Therapie der myelombedingten Nierenerkrankung Katja Weisel, Tübingen Fragen zum Vortrag 14:30 14:50 Kaffeepause 14:50 15:30 Sitzung VII Therapieempfehlungen bei Patienten mit Multiplem Myelom II Vorsitzende: Katja Weisel, Tübingen, Kai Neben, Heidelberg CV Abstract Slides 14:50 15:10 Die Therapie der Knochenerkrankung beim Multiplen Myelom Franz Jakob, Würzburg Fragen zum Vortrag 15:10 15:30 Neue Therapieoptionen für das Multiple Myelom welche Fortschritte erwarten wir innerhalb der nächsten Jahre? Marc-Steffen Raab, Heidelberg Fragen zum Vortrag 15:30 16:00 Resümee des 14 th International Myeloma Workshop : 114 Welche diagnostischen und therapeutischen Konsequenzen ergeben sich für die Patientenversorgung in Deutschland? Hartmut Goldschmidt, Heidelberg, Hermann Einsele, Würzburg Seite 10 Seite 11

7 CURRICULUM VITAE The Emerging Role of Novel Therapies in the Management of Multiple Myeloma (MM) Paul Richardson, Boston, MA, USA Paul Richardson Paul Richardson MD is the RJ Corman Professor of Medicine at Harvard Medical School and Clinical Director of the Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute (DFCI), Boston, USA. Dr Richardson obtained his medical degree from St Bartholomew s Hospital Medical College, London, UK, before completing residencies at Newcastle University School of Medicine, UK, the Royal Marsden Hospital (London and Surrey) and then the Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, USA. His fellowships in haematology/oncology and medical oncology were completed at Tufts University School of Medicine, Baystate Medical Center, Springfield, USA, and Harvard Medical School, DFCI. Dr Richardson s primary research interest is in novel therapies for myeloma, including bortezomib, lenalidomide and pomalidomide, and he is currently a clinical leader for multiple studies on the use of combination therapies in the treatment of this disease. He is serving as Principal or Co Principal Investigator and Study Chair for several pivotal trials, including the international Intergroupe Francophone du Myélome/DFCI 2009 study in newly diagnosed patients eligible for stem cell transplantation using the combination of lenalidomide, bortezomib and dexamethasone (RVD). His role in the development of defibrotide for the treatment of veno-occlusive disease began with its very inception, when he treated the first patient and then led the first clinical study for this indication. Since then Dr Richardson has had a central role in all the US prospective clinical trials performed to date, with a number of orphan product drug grants awarded by the FDA to facilitate and support the evaluation of the drug as part of his investigator-initiated studies, as well as an early phase development grant from the American Cancer Society. Among other honours, Dr Richardson was awarded an honorary Fellowship of the Royal College of Physicians (UK) in recognition of his international contributions in multiple myeloma and stem cell transplantation. He is the past Chair of the Multiple Myeloma Research Consortium (USA) Clinical Trials Core, a position he held for 5 years as a founding member and as part of a rotating tenure, and for which he currently serves on the Steering Committee and Project Review Committee. He is Chair of the newly formed Alliance Myeloma Committee (USA), formerly known as the Cancer and Leukemia Group B. The last decade has seen remarkable progress in the therapy of MM with the development of combination regimens that incorporate the proteasome inhibitor Bortezomib and the immunomodulatory agents Thalidomide and Lenalidomide, as well as the recent approval of Carfilzomib and Pomalidomide. Advances have been predicated on greater understanding of MM biology and the interaction with the marrow microenvironment as well as cortical bone. With the incorporation of novel agents as targeted therapy, median survival has significantly improved. Furthermore, with the integration of novel therapies around established standards of care, further improvements have been achieved. Specifically, the use of novel treatments around autologous stem cell transplantation (ASCT) and the emerging treatment paradigm of induction, intensification, consolidation and maintenance applied across both transplant eligible and ineligible patients has emerged as a key treatment algorithm. However, in spite of these advances, nearly all patients relapse, as reflected by the lack of any plateau in survival curves from clinical trials evaluating currently available treatment options. Substantial challenges thus remain, and MM remains incurable. The optimal sequencing and integration of treatment strategies has become increasingly important as survival has improved. Both acute and long-term toxicities include peripheral neuropathy, thromboembolic disease, myelosuppression, and the interaction of traditional genotoxic treatment with immunomodulatory agents which may result in rare complications such as second new primaries. Further research including pharmacogenetic analysis of patient DNA and trials to assess the efficacy of interventions to minimize toxicity are thus essential to further improve patient outcome. Novel combination therapies which are rationally designed and derived from bench research utilizing informative models have proven central to progress. Second generation small molecules are under development as part of combination strategies, which build upon the therapeutic backbone of immunomodulatory therapy and proteasome inhibition. Monoclonal antibodies are now finding their place in the therapeutic armamentarium. Further refinement of ASCT and its utilization in selected patients, versus sparing this in others and keeping ASCT in reserve, is currently under study. Allogeneic SCT remains investigational, but will also hopefully benefit from the integration of novel therapies, making it a modality associated with less toxicity and greater efficacy. In summary, improvements to help understand heterogeneity in MM and the complexities of its biology through genomics and proteomics should enhance the ability to pursue more tailored treatments. This, together with continued new drug development, offers the potential of yet further clinical benefit and the increased probability of making MM a chronic illness in the majority of patients. Dr Richardson is an editorial board member of several journals, including the Journal of Clinical Oncology and the British Journal of Haematology, and has authored or co-authored over 350 articles published in international, peerreviewed journals, including several original papers in the New England Journal of Medicine. Seite 12 Seite 13

8 Seite 14 Seite 15

9 CURRICULUM VITAE Molecular development of Multiple Myeloma role of Cereblon Gareth Morgan, London, UK Gareth Morgan Gareth Morgan is Professor of Haematology at The Institute of Cancer Research (ICR) and Consultant Haematologist at the Royal Marsden NHS Foundation Trust. After attending medical school at the University Hospital of Wales, he completed a PhD and trained in the molecular genetics and management of blood cell cancers at the ICR. He left the ICR to join the University of Leeds where he set up his own research group studying the molecular genetics of non-hodgkin s lymphoma and myeloma. During this time, he developed his interest and expertise in the treatment and management of leukaemias, lymphomas and myeloma. He is an internationally respected clinician and researcher who has published extensively on the genetics and treatment of these diseases. His research has focussed on the translation of information derived from the molecular analysis of the pathogenesis of malignant cells into the clinic using novel targeted treatment strategies based on innovative diagnostic approaches. One of the major aims of his research group is the development of personalised medicine strategies for myeloma with the aim of overcoming treatment resistance. In particular, he is interested in the use of new drugs in the context of standard treatment approaches. He is a committed clinician and trialist and is currently Principal Investigator of the Myeloma XI study and a number of Phase I and II studies, as well as serving on Independent Data Monitoring Committees. He is actively involved in research into the genetic basis of myeloma and how this can be used in the clinical environment. He receives programme funding from Myeloma UK as well as project support from the Kay Kendall Leukaemia Fund, the Bud Flanagan Leukemia Fund and Cancer Research UK. He is widely published with over 400 high impact factor peer reviewed articles. He is recognised nationally and internationally as a clinician and researcher and has been Scientific Secretary for the British Society of Haematology. He is currently Scientific Secretary for the UK Myeloma Forum. He reviews for a number of journals and sits on grant giving bodies both in the UK and internationally. He has been instrumental in the establishment of the European Myeloma Network. He is a Director for Myeloma UK, Scientific Advisor to the International Myeloma Foundation and is on the Board of the UK Stem Cell Bank. Seite 16 Seite 17

10 CURRICULUM VITAE Genome wide association studies (GWAS) and prediction of cancer Richard Houlston, London, UK Richard Houlston Current Post Professor of Molecular and Population Genetics, Division of Genetics and Epidemiology, Institute of Cancer Research; Honorary Consultant in Clinical Genetics, Royal Marsden NHS Trust, UK Education Imperial College, London BSc (Biochemistry), MB BS (Distinction Pathology); MRC Studentship, Dermatology Prize Institute of Psychiatry, University of London; MSc University of London; MD, PhD (Genetics) Further Qualifications MRCPath 1988, FRCPath 1997, MRCP 1992, FRCP 1997 Specialist accreditation in pathology 1988 Specialist accreditation in genetics (JCHMT) 1992 Publications Over 370 articles in peer-reviewed journals Over 60 book chapters and review articles Employment Reader in Molecular and Population Genetics, Institute of Cancer Research Senior Lecturer in Genetics, Institute of Cancer Research Clinical Scientist, Institute of Cancer Research 1992 Specialist Registrar in Clinical Genetics, Southampton University Clinical Research Fellow, Imperial Cancer Research Fund Lecturer UMDS, London Wellcome Trust Clinical Fellow, Institute of Psychiatry, London House Officer and Registrar Posts Memberships of Academic Committees and Boards 2012 present Academy of Medical Sciences: Sectional Committee Membership ; Cancer family study group 2006 present UkCCS steering committee 2001 present Institute of Cancer Research, Academic Board 2002 present Institute of Cancer Research-Royal Mardsen Hospitals NHS Trust, Joint Research Committee Seite 18 Seite 19

11 CURRICULUM VITAE Role of new imaging techniques in diagnosing and staging of patients with Multiple Myeloma Stefan Delorme, Heidelberg, Germany In our center, plain films are obsolete, and have been replaced by whole-body CT for detecting destruction of mineralized bone. Nevertheless, new open questions have arisen. First, the imaging criteria for staging are still divergent. Second, there is disagreement which imaging techniques should be used in future, and in which combination. Third, using more sensitive techniques will inevitably cause patients to be staged higher than they would if only plain films were used, but the consequences with regard to treatment are unclear. In particular, the relevance of diffuse infiltration patterns seen with MRI only is open. Stefan Delorme 1987 Graduated from Medical School in Hannover, Approbation, Assumed German citizenship Resident in Internal Medicine, I. Medizinische Universitätsklinik Heidelberg 1988 Medical Dissertation (Dr. med.) Resident in Radiology, DKFZ Working group leader in CT and Ultrasonography Resident, Department of Radiology, Heidelberg University Resident in Radiology, DKFZ 1996 Board certification in Radiology, supervising physician and research fellow, DKFZ Since 1998 Deputy chairman of the Derpartment of Radiology, DKFZ 1999 Habilitation and appointment as Associate Professor in Radiology (Heidelberg University) 1999 Appointment as Senior Teacher in the German Society of Ultrasound in Medicine (DEGUM) Working group leader in MRI Acting chairman of the Department of Oncological Diagnostics and Therapy, DKFZ Since 2003 Working group leader in Body and Musculoskeletal imaging Chairman of the Radiological section of the German Society of Ultrasound in Medicine (DEGUM) Acting chairman of the Department of Radiology, DKFZ Since 2010 Vice chairman of the Department of Radiology, DKFZ President elect of the German Society of Ultrasound in Medicine (DEGUM) Since 2010 President of the German Society of Ultrasound in Medicine (DEGUM) New imaging techniques whole-body computed tomography (CT), whole-body magnetic resonance imaging (MRI), positron emission tomography (PET) with 18-F-deoxyglucose (FDG) - have proven advantageous for imaging multiple myeloma: 1. All lesions leading to bone destructions visible on plain films will also be seen with CT or MRI. 2. CT and MRI will also show lesions which have not yet caused a destruction of mineralized bone, which extend beyond the confines of the bone, or which are primarily extraskeletal. While MRI will show intraosseous lesions irrespective of their location, CT will detect lesions mainly if they lie within fatty but not hematopoietic bone marrow. 3. MRI but not CT or plain films will reliably show a diffuse myeloma infiltration in the bone marrow, even if the cancellous bone is still preserved. This will only be depicted by CT if the bone is very osteoporotic. 4. CT of the entire skeleton can be performed within one minute in low-dose technique without effort for the patient, and with a radiation dose comparable to plain films. 5. MRI is highly sensitive to any lesion, and a normal MRI excludes lytic lesions which could possibly be detected with CT or plain films. However, once a lesion is found with MRI, additional CT or plain films may be needed to assess alterations of mineralized bone and their impact on its stability. 6. Diffusion-weighted MRI (DWI) with background suppression will sensitively detect areas of increased cellular density within the bone marrow, particularly bone marrow infiltrates. DWI is being evaluated as a possible tool for assessing local aggressiveness and treatment response. 7. FDG-PET is less sensitive in detecting myeloma infiltrates than MRI. It is insensitive to diffuse bone marrow involvement but may show solid nodules if they are metabolically active. Despite its low sensitivity its value may lie in the detection of mainly active nodules. It is not clear yet, however whether these are more clinically relevant than those with a lower uptake. A treatment response is mirrored in a reduction in FDG uptake, which occurs earlier than a morphological shrinkage of lesions. Seite 20 Seite 21

12 Seite 22 Seite 23

13 CURRICULUM VITAE Role for genomics in Multiple Myeloma Hervé Avet-Loiseau, Toulouse, France Hervé Avet-Loiseau Hervé Avet-Loiseau has been Head of the Laboratory for Genomics in Myeloma at the University Cancer Center of Toulouse, France since September Previously, he was Head of the Hematology Laboratory at the University Hospital of Nantes, France, a position he held from He received his medical degree with a specialization in pediatric hematology in After pursuing a postdoctoral fellowship in the laboratory of Dr Joe Gray in San Francisco, USA, he moved into the area of biological hematology in 1995 and subsequently specialized in cytogenetics. He received his PhD in 1998 and became Professor of Hematology in Professor Avet-Loiseau is highly involved in the Intergroupe Francophone du Myélome (IFM), where he leads all biological studies. Most of these studies are based on the analysis of genetic abnormalities observed in malignant plasma cells using different technologies, including fluorescence in situ hybridization (FISH), gene expression profiling, and single nucleotide polymorphism (SNP) arrays. In March 2011, Professor Avet-Loiseau was elected President of the IFM. Seite 24 Seite 25

14 Seite 26 Seite 27

15 CURRICULUM VITAE From myeloma precursor disease to Multiple Myeloma Maria-Victoria Mateos, Salamanca, Spain Should we treat Smoldering Multiple Myeloma? Smoldering Multiple Myeloma (SMM) is an asymptomatic precursor disease of MM for which the standard of care is observation until progression to symptomatic disease occurs. Maria-Victoria Mateos Dr. María-Victoria Mateos, MD and PhD, is an Associated Professor and Consultant Physician of the Haematology Department at the University Hospital of Salamanca, Spain. She studied Medicine at the University of Valladolid, Spain ( ) and completed her residency in Haematology at the University Hospital of Salamanca. In 2000, she obtained her PhD (Methylation of the p16 gene in Multiple Myeloma). Currently, she works as clinician physician and coordinates all clinical trials developed in the Haematology Department, collaborating in the design together with their development. She is a member of the PETHEMA board in Spain due to her active participation in the clinical trials and also she is a member of the IMWG due to her participation in clinical trials focused on Multiple Myeloma. She has published over 100 original papers in international journals. Her areas of interest include multiple myeloma, the biology of plasma cells and the news drugs development. However, SMM is a heterogeneous disease and although there are SMM patients at low or standard risk of progression who won t obtain any benefit from an early treatment, there is a high-risk subgroup of patients in whom the median time to progression to active disease is of approximately 2 years and these should really be the target for an early intervention. All attempts to early treat SMM patients, including alkylators agents, thalidomide, or bisphosphonates, failed to obtain a benefit but no discrimination according to the risk of progression was done. Currently, several trials are ongoing in high risk SMM patients with different drugs (lenalidomide, siltuximab, elotuzumab, MLN9708) and we have already consolidated results from a trial conducted by the Spanish Myeloma Group in this selected patient population comparing lenalidomide-based therapy vs. observation. The early treatment with lenalidomide-dexamethasone followed by lenalidomide maintenance significantly delayed the time to progression to symptomatic disease, and resulted into a benefit in overall survival. In addition, the oral administration of this regimen was convenient for the patients with a good toxicity profile. We conclude that, at the present time, we are in the optimal way to change the paradigm of treatment of SMM patients at high risk of progression to active disease. Seite 28 Seite 29

16 Seite 30 Seite 31

17 CURRICULUM VITAE Familial risks and germline genetics of Myeloma Kari Hemminki, Heidelberg, Germany Kari Hemminki Position Title Professor of Molecular Genetic Epidemiology Education/Training 1973 University of Helsinki, Finland, MD, Medicine 1973 University of Helsinki, Finland, PhD, Medical biochemistry 1975 University of Helsinki, Finland, Assist. Prof, Medical biochemistry Johns Hopkins University, Baltimore, USA, Postdoc, Molecular biology Positions Research Professor, Institute of Occupational Health, Helsinki Professor of Epidemiology, Karolinska Institute, Huddinge, Sweden (from at 20%) since 2002 Professor of Molecular Genetic Epidemiology, German Cancer Research Center (DKFZ) and since 2006 University of Heidelberg, Heidelberg, Germany German Cancer Research Center, chairperson of research area C, Cancer Risk Factors and Prevention and member of the scientific council Foreign Adjunct Professor, molecular genetic epidemiology, Karolinska Institute, Sweden since 2009 Guest Professor, molecular genetic epidemiology, Lund University Little is known about genetic susceptibility to multiple myeloma (MM). According to the Swedish Family-Cancer Database, the familial risk of MM is close 3.0 which is among the highest of common malignancies. The likelihood of finding significant genetic effects is grossly related to the magnitude of the familial risk, which is a surrogate of heritability. The familial risk is thus a roadmap into disease genetics, which would thus suggest that susceptibility genes exist for MM. Indeed, the first genome wide association study (GWAS), conducted as a UK-German collaboration by Broderick and coworkers (Nature Genet 2012), identified risk loci at 3p22.1 (rs in ULK4; odds ratio (OR) = 1.32; P = ) and 7p15.3 (rs , OR = 1.38; P = ). In addition, we observed a promising association at 2p23.3 (rs , OR = 1.29; P = ). The G-to-A transition at rs of the ULK 4 gene results in an alanine to threonine alteration, which is predicted to be benign. The gene encodes a serine/threonine protein kinase, which is a key regulator of mtor-mediated autophagy. The rs SNP at chromosome 7 maps to an intron of the DNAH11 gene, which encodes a dynein heavy chain microtubuledependent ATPase motor, involved in respiratory cilia movement. Germline DNAH11 mutations cause Kartagener syndrome. However, the SNP is in linkage disequilibrium with the CDCA7L gene, encoding a MYC interacting protein. The risks for MM conferred by these three loci collectively accounting for only ~4% of the familial risk of MM. However, because of the high carrier frequencies of risk alleles, the loci make a significant contribution to MM etiology in terms of the population attributable fraction of ~37%. The chromosome 3 locus was recently associated with the risk of monoclonal gammopathy of undetermined significance (Greenberg et al, Leukemia 2012). MM shows many types of cytogenetic changes, some of which have prognostic implications. However, little is known about the possible genetic control of these changes. We have addressed this question in our joint UK-German MM population. Common cytogenetetic abnormalities were assessed by interphase fluorescence in situ hybridization (FISH) and the frequencies were associated with SNP data from the joint GWAS. According to the preliminary results, some significant associations were discovered. Support: German Cancer Aide. Seite 32 Seite 33

18 Seite 34 Seite 35

19 CURRICULUM VITAE Immunomodulatory drugs incorporated into maintenance strategies Philippe Moreau, Nantes, France 1 - Maintenance with IMiDs following high-dose therapy (HDT) and autologous stem cell transplantation (ASCT) Philippe Moreau Prof. Philippe Moreau, MD, is Head of the Hematology Department at the University Hospital of Nantes, France. He specializes in clinical hematology, with a particular focus on multiple myeloma and its treatment with high-dose therapy and novel agents. Prof. Moreau was appointed University Professor of Clinical Hematology at Nantes Faculty of Medicine in As leading researcher in multiple myeloma, Prof. Moreau is head of the unit for early phase 1 and phase 2 trials in clinical hematology at the University Hospital of Nantes. Additionally, he was a member of the organizing committee for the 2011 International Myeloma Workshop, in Paris. Prof. Moreau is currently a member of the administration council f the Intergroupe Francophone du Myélome (IFM), and he was chairman of the IFM from 2006 through Prof. Moreau is widely published, with more than 200 per-reviewed articles and reviews that have appeared in high impact factor journals including Journal of Clinical Oncology, Lancet Oncology, and Blood. He is frequently invited speaker at international hematologic oncology meetings. In most countries, thalidomide was the first novel agent to become available. This oral drug was soon examined ASCT in the maintenance setting, with the objective of prolonging the duration of response. Six randomized phase III studies from various countries have since been published. Taken together, all 6 trials have shown a significant benefit for thalidomide in terms of response and progression-free survival (PFS), while overall survival (OS) was improved in two of these studies. The safety profile of thalidomide may hinder its use as long-term maintenance therapy. Notably, peripheral neuropathy (PN) observed with thalidomide is cumulative and related to treatment duration. The incidence of PN was high across all trials, and was the main cause of discontinuation of maintenance therapy. The possible emergence of tumor-resistant clones in patients with prolonged exposure to thalidomide has also led to concerns about its lack of efficacy in patients with adverse cytogenetic abnormalities. Lenalidomide is currently considered the best candidate for use as maintenance therapy. Results from two randomized trials evaluating lenalidomide maintenance following ASCT have recently been published. In the IFM study, 614 patients received lenalidomide consolidation treatment after ASCT and were then randomized to receive either placebo (Arm A) or lenalidomide maintenance (10 15 mg/day until relapse; Arm B). After a median follow-up of 30 months, patients who received lenalidomide maintenance had improved median PFS by 18 months (median 23 months in Arm A versus 41 months in Arm B). A benefit in terms of OS has not yet been demonstrated. Second primary malignancies (SPMs) were observed in 26 patients (3,1 %) treated with lenalidomide and 11 (1,2%) treated with placebo. The Cancer and Leukemia Group B (CALGB) group reported the results of a similar phase III randomized trial of lenalidomide or placebo following HDT and ASCT (CALGB study). Patients (N = 460) aged <70 years with non-progressive multiple myeloma were randomized post-asct to receive placebo (n = 229) or lenalidomide 10 mg/day (n = 231) until progression. The study was stopped prematurely because of the significant superiority observed with lenalidomide maintenance, which resulted in a 63% reduction in the risk of progression compared with placebo. The median time-to-progression (TTP) was 46 months for the lenalidomide arm versus 27 months for the placebo arm at a median follow-up of 34 months. Interestingly, despite a crossover of patients with disease progression from the placebo arm to the lenalidomide arm, an improvement in OS was observed favoring the lenalidomide arm (3-year OS rate: 88% versus 80%; P=0.03). Eighteen of the 231 patients treated with lenalidomide developed SPMs (7.8%), whereas 6 of the 229 patients (2.6%) treated with placebo developed SPMs. 2 - Maintenance with IMiDs in patients non eligible for ASCT Maintaining response to induction treatment and preventing tumor progression are important goals also in elderly patients. Thalidomide maintenance may be an option, although thalidomide tolerance decreases with aging. Three of the six Melphalan-Prednisone-Thalidomide (MPT) studies included thalidomide maintenance, but no OS advantage was observed. Two other trials explored the role of thalidomide maintenance after conventional therapy, demonstrating an improvement in PFS, but not in OS, probably due to a slight increase in toxicity. Lenalidomide is another attractive drug in the maintenance setting. However, its routine use is controversial, given the concerns about the risk of SPMs observed following ASCT. In a pre-specified landmark analysis of the MM015 trial, lenalidomide maintenance significantly extended median PFS from the start of maintenance (26 months) as compared with placebo (7 months), regardless of age and with acceptable adverse-event rates. The results of the trial confirm the importance of continuous treatment with lenalidomide. The data available so far suggest that maintenance treatment has the potential to improve PFS. However, longer follow-up is needed to assess the survival benefit, to define the appropriate duration, and the impact of maintenance treatment on survival at relapse. Seite 36 Seite 37

20 Seite 38 Seite 39

Prediction Market, 28th July 2012 Information and Instructions. Prognosemärkte Lehrstuhl für Betriebswirtschaftslehre insbes.

Prediction Market, 28th July 2012 Information and Instructions. Prognosemärkte Lehrstuhl für Betriebswirtschaftslehre insbes. Prediction Market, 28th July 2012 Information and Instructions S. 1 Welcome, and thanks for your participation Sensational prices are waiting for you 1000 Euro in amazon vouchers: The winner has the chance

Mehr

Aktuelle Behandlungsstrategien Studien des European MCL net Prof. Dr. Martin Dreyling Medizinische Klinik III LMU München

Aktuelle Behandlungsstrategien Studien des European MCL net Prof. Dr. Martin Dreyling Medizinische Klinik III LMU München Medizinische Klinik und Poliklinik III Direktor: Prof. Dr. W. Hiddemann Aktuelle Behandlungsstrategien Studien des European MCL net Prof. Dr. Martin Dreyling Medizinische Klinik III LMU München Disclosures

Mehr

University of Tirana

University of Tirana University of Tirana Address: Sheshi Nënë Tereza ; www.unitir.edu.al Tel: 04228402; Fax: 04223981 H.-D. Wenzel, Lehrstuhl Finanzwissenschaft, OFU Bamberg 1 University of Tirana The University of Tirana

Mehr

TMF projects on IT infrastructure for clinical research

TMF projects on IT infrastructure for clinical research Welcome! TMF projects on IT infrastructure for clinical research R. Speer Telematikplattform für Medizinische Forschungsnetze (TMF) e.v. Berlin Telematikplattform für Medizinische Forschungsnetze (TMF)

Mehr

Einsatz einer Dokumentenverwaltungslösung zur Optimierung der unternehmensübergreifenden Kommunikation

Einsatz einer Dokumentenverwaltungslösung zur Optimierung der unternehmensübergreifenden Kommunikation Einsatz einer Dokumentenverwaltungslösung zur Optimierung der unternehmensübergreifenden Kommunikation Eine Betrachtung im Kontext der Ausgliederung von Chrysler Daniel Rheinbay Abstract Betriebliche Informationssysteme

Mehr

Mediziner nur noch Ärzte oder auch noch Forscher?

Mediziner nur noch Ärzte oder auch noch Forscher? Mediziner nur noch Ärzte oder auch noch Forscher? Prof. em. Dr. med. Peter Meier-Abt, Schweizerischen Akademie der Medizinischen Wissenschaften (SAMW) Basel Erfolge von Wissenschaften und Innovationen

Mehr

Cluster Health Care Economy has been established in 2008 Regional approach to develop health care industries Head of the cluster is Ms.

Cluster Health Care Economy has been established in 2008 Regional approach to develop health care industries Head of the cluster is Ms. How to develop health regions as driving forces for quality of life, growth and innovation? The experience of North Rhine-Westphalia Dr. rer. soc. Karin Scharfenorth WHO Collaborating Centre for Regional

Mehr

Understanding and Improving Collaboration in Distributed Software Development

Understanding and Improving Collaboration in Distributed Software Development Diss. ETH No. 22473 Understanding and Improving Collaboration in Distributed Software Development A thesis submitted to attain the degree of DOCTOR OF SCIENCES of ETH ZURICH (Dr. sc. ETH Zurich) presented

Mehr

Lehrstuhl für Allgemeine BWL Strategisches und Internationales Management Prof. Dr. Mike Geppert Carl-Zeiß-Str. 3 07743 Jena

Lehrstuhl für Allgemeine BWL Strategisches und Internationales Management Prof. Dr. Mike Geppert Carl-Zeiß-Str. 3 07743 Jena Lehrstuhl für Allgemeine BWL Strategisches und Internationales Management Prof. Dr. Mike Geppert Carl-Zeiß-Str. 3 07743 Jena http://www.im.uni-jena.de Contents I. Learning Objectives II. III. IV. Recap

Mehr

treffen und informieren Der Teva-Kongress-Service für den onkologisch verantwortlichen Arzt ASH 2014 San Francisco Programm Teva Onkoversum

treffen und informieren Der Teva-Kongress-Service für den onkologisch verantwortlichen Arzt ASH 2014 San Francisco Programm Teva Onkoversum treffen und informieren Der Teva-Kongress-Service für den onkologisch verantwortlichen Arzt ASH 2014 San Francisco Programm Teva Onkoversum Der Teva-Kongress-Service für den onkologisch verantwortlichen

Mehr

The poetry of school.

The poetry of school. International Week 2015 The poetry of school. The pedagogy of transfers and transitions at the Lower Austrian University College of Teacher Education(PH NÖ) Andreas Bieringer In M. Bernard s class, school

Mehr

Exercise (Part II) Anastasia Mochalova, Lehrstuhl für ABWL und Wirtschaftsinformatik, Kath. Universität Eichstätt-Ingolstadt 1

Exercise (Part II) Anastasia Mochalova, Lehrstuhl für ABWL und Wirtschaftsinformatik, Kath. Universität Eichstätt-Ingolstadt 1 Exercise (Part II) Notes: The exercise is based on Microsoft Dynamics CRM Online. For all screenshots: Copyright Microsoft Corporation. The sign ## is you personal number to be used in all exercises. All

Mehr

Titelbild1 ANSYS. Customer Portal LogIn

Titelbild1 ANSYS. Customer Portal LogIn Titelbild1 ANSYS Customer Portal LogIn 1 Neuanmeldung Neuanmeldung: Bitte Not yet a member anklicken Adressen-Check Adressdaten eintragen Customer No. ist hier bereits erforderlich HERE - Button Hier nochmal

Mehr

Field Librarianship in den USA

Field Librarianship in den USA Field Librarianship in den USA Bestandsaufnahme und Zukunftsperspektiven Vorschau subject librarians field librarians in den USA embedded librarians das amerikanische Hochschulwesen Zukunftsperspektiven

Mehr

Inequality Utilitarian and Capabilities Perspectives (and what they may imply for public health)

Inequality Utilitarian and Capabilities Perspectives (and what they may imply for public health) Inequality Utilitarian and Capabilities Perspectives (and what they may imply for public health) 1 Utilitarian Perspectives on Inequality 2 Inequalities matter most in terms of their impact onthelivesthatpeopleseektoliveandthethings,

Mehr

Verleihung der Röntgen-Plakette 2013

Verleihung der Röntgen-Plakette 2013 Verleihung der Röntgen-Plakette 2013 Die Verleihung der Röntgen-Plakette findet in diesem Jahr statt. am Samstag, dem 04. Mai 2013 um 11.00 Uhr im Röntgen-Gymnasium in Remscheid-Lennep (Röntgenstraße 12)

Mehr

1. General information... 2 2. Login... 2 3. Home... 3 4. Current applications... 3

1. General information... 2 2. Login... 2 3. Home... 3 4. Current applications... 3 User Manual for Marketing Authorisation and Lifecycle Management of Medicines Inhalt: User Manual for Marketing Authorisation and Lifecycle Management of Medicines... 1 1. General information... 2 2. Login...

Mehr

A. Wutte, J. Plank, M. Bodenlenz, C. Magnes, W. Regittnig, F. Sinner, B. Rønn, M. Zdravkovic, T. R. Pieber

A. Wutte, J. Plank, M. Bodenlenz, C. Magnes, W. Regittnig, F. Sinner, B. Rønn, M. Zdravkovic, T. R. Pieber Proportional ose Response Relationship and Lower Within Patient Variability of Insulin etemir and NPH Insulin in Subjects With Type 1 iabetes Mellitus A. Wutte, J. Plank, M. Bodenlenz, C. Magnes, W. Regittnig,

Mehr

Abteilung Internationales CampusCenter

Abteilung Internationales CampusCenter Abteilung Internationales CampusCenter Instructions for the STiNE Online Enrollment Application for Exchange Students 1. Please go to www.uni-hamburg.de/online-bewerbung and click on Bewerberaccount anlegen

Mehr

CHAMPIONS Communication and Dissemination

CHAMPIONS Communication and Dissemination CHAMPIONS Communication and Dissemination Europa Programm Center Im Freistaat Thüringen In Trägerschaft des TIAW e. V. 1 CENTRAL EUROPE PROGRAMME CENTRAL EUROPE PROGRAMME -ist als größtes Aufbauprogramm

Mehr

Algorithms for graph visualization

Algorithms for graph visualization Algorithms for graph visualization Project - Orthogonal Grid Layout with Small Area W INTER SEMESTER 2013/2014 Martin No llenburg KIT Universita t des Landes Baden-Wu rttemberg und nationales Forschungszentrum

Mehr

Possible Solutions for Development of Multilevel Pension System in the Republic of Azerbaijan

Possible Solutions for Development of Multilevel Pension System in the Republic of Azerbaijan Possible Solutions for Development of Multilevel Pension System in the Republic of Azerbaijan by Prof. Dr. Heinz-Dietrich Steinmeyer Introduction Multi-level pension systems Different approaches Different

Mehr

p^db=`oj===pìééçêíáåñçêã~íáçå=

p^db=`oj===pìééçêíáåñçêã~íáçå= p^db=`oj===pìééçêíáåñçêã~íáçå= Error: "Could not connect to the SQL Server Instance" or "Failed to open a connection to the database." When you attempt to launch ACT! by Sage or ACT by Sage Premium for

Mehr

Eckpunkte des sog.rheumavertrages

Eckpunkte des sog.rheumavertrages Eckpunkte des sog.rheumavertrages Titel: Vereinbarung zur Förderung der wirtschaftlichen Verordnung von Arzneimitteln in der Therapie der rheumatoiden Arthritis gemäß 84 Abs. 1 Satz 5 SGB V Rahmenvertrag

Mehr

USBASIC SAFETY IN NUMBERS

USBASIC SAFETY IN NUMBERS USBASIC SAFETY IN NUMBERS #1.Current Normalisation Ropes Courses and Ropes Course Elements can conform to one or more of the following European Norms: -EN 362 Carabiner Norm -EN 795B Connector Norm -EN

Mehr

ISO 15504 Reference Model

ISO 15504 Reference Model Prozess Dimension von SPICE/ISO 15504 Process flow Remarks Role Documents, data, tools input, output Start Define purpose and scope Define process overview Define process details Define roles no Define

Mehr

Ingenics Project Portal

Ingenics Project Portal Version: 00; Status: E Seite: 1/6 This document is drawn to show the functions of the project portal developed by Ingenics AG. To use the portal enter the following URL in your Browser: https://projectportal.ingenics.de

Mehr

Vocational Education and Training (VET) in Switzerland and Schaffhausen

Vocational Education and Training (VET) in Switzerland and Schaffhausen Presentation at Information Event February 18, 2015 Karin Baumer, Office for Vocational Education and Training Vocational Education and Training (VET) in Switzerland and Schaffhausen Seite 1 Commercial

Mehr

eurex rundschreiben 094/10

eurex rundschreiben 094/10 eurex rundschreiben 094/10 Datum: Frankfurt, 21. Mai 2010 Empfänger: Alle Handelsteilnehmer der Eurex Deutschland und Eurex Zürich sowie Vendoren Autorisiert von: Jürg Spillmann Weitere Informationen zur

Mehr

Extract of the Annotations used for Econ 5080 at the University of Utah, with study questions, akmk.pdf.

Extract of the Annotations used for Econ 5080 at the University of Utah, with study questions, akmk.pdf. 1 The zip archives available at http://www.econ.utah.edu/ ~ ehrbar/l2co.zip or http: //marx.econ.utah.edu/das-kapital/ec5080.zip compiled August 26, 2010 have the following content. (they differ in their

Mehr

Introduction to the diploma and master seminar in FSS 2010. Prof. Dr. Armin Heinzl. Sven Scheibmayr

Introduction to the diploma and master seminar in FSS 2010. Prof. Dr. Armin Heinzl. Sven Scheibmayr Contemporary Aspects in Information Systems Introduction to the diploma and master seminar in FSS 2010 Chair of Business Administration and Information Systems Prof. Dr. Armin Heinzl Sven Scheibmayr Objective

Mehr

DIGICOMP OPEN TUESDAY AKTUELLE STANDARDS UND TRENDS IN DER AGILEN SOFTWARE ENTWICKLUNG. Michael Palotas 7. April 2015 1 GRIDFUSION

DIGICOMP OPEN TUESDAY AKTUELLE STANDARDS UND TRENDS IN DER AGILEN SOFTWARE ENTWICKLUNG. Michael Palotas 7. April 2015 1 GRIDFUSION DIGICOMP OPEN TUESDAY AKTUELLE STANDARDS UND TRENDS IN DER AGILEN SOFTWARE ENTWICKLUNG Michael Palotas 7. April 2015 1 GRIDFUSION IHR REFERENT Gridfusion Software Solutions Kontakt: Michael Palotas Gerbiweg

Mehr

Exercise (Part XI) Anastasia Mochalova, Lehrstuhl für ABWL und Wirtschaftsinformatik, Kath. Universität Eichstätt-Ingolstadt 1

Exercise (Part XI) Anastasia Mochalova, Lehrstuhl für ABWL und Wirtschaftsinformatik, Kath. Universität Eichstätt-Ingolstadt 1 Exercise (Part XI) Notes: The exercise is based on Microsoft Dynamics CRM Online. For all screenshots: Copyright Microsoft Corporation. The sign ## is you personal number to be used in all exercises. All

Mehr

Accreditation of Prior Learning in Austria

Accreditation of Prior Learning in Austria Accreditation of Prior Learning in Austria Birgit Lenger ibw Institut für Bildungsforschung der Wirtschaft Institute for Research on Qualifications and Training of the Austrian Economy October, 2009 TOPICS

Mehr

beim Multiplen Myelom

beim Multiplen Myelom Auto-TPX beim Multiplen Myelom Kai Neben/Maximilian Merz/Jana Schlenzka/Hartmut Goldschmidt Klinikum Baden Baden Universitätsklinikum tsklinikum Heidelberg NCT Heidelberg Medizinische Klinik V 1 Myelom

Mehr

Labour law and Consumer protection principles usage in non-state pension system

Labour law and Consumer protection principles usage in non-state pension system Labour law and Consumer protection principles usage in non-state pension system by Prof. Dr. Heinz-Dietrich Steinmeyer General Remarks In private non state pensions systems usually three actors Employer

Mehr

Extended Ordered Paired Comparison Models An Application to the Data from Bundesliga Season 2013/14

Extended Ordered Paired Comparison Models An Application to the Data from Bundesliga Season 2013/14 Etended Ordered Paired Comparison Models An Application to the Data from Bundesliga Season 2013/14 Gerhard Tutz & Gunther Schauberger Ludwig-Maimilians-Universität München Akademiestraße 1, 80799 München

Mehr

Welche Rolle kann gemeinwohlorientierte Wissenschaft/Forschungspolitik für die Entwicklung und Umsetzung einer zukunftsfähigen Green Economy spielen?

Welche Rolle kann gemeinwohlorientierte Wissenschaft/Forschungspolitik für die Entwicklung und Umsetzung einer zukunftsfähigen Green Economy spielen? Welche Rolle kann gemeinwohlorientierte Wissenschaft/Forschungspolitik für die Entwicklung und Umsetzung einer zukunftsfähigen Green Economy spielen? - In welcher Verbindung stehen gemeinwohlorientierte

Mehr

Customer-specific software for autonomous driving and driver assistance (ADAS)

Customer-specific software for autonomous driving and driver assistance (ADAS) This press release is approved for publication. Press Release Chemnitz, February 6 th, 2014 Customer-specific software for autonomous driving and driver assistance (ADAS) With the new product line Baselabs

Mehr

It's just a laboratory, it is not your life.

It's just a laboratory, it is not your life. It's just a laboratory, it is not your life. Stressors and starting points for health promoting interventions in medical school from the students perspective: a qualitative study. 20.04.2015 Thomas Kötter,

Mehr

GIPS 2010 Gesamtüberblick. Dr. Stefan J. Illmer Credit Suisse. Seminar der SBVg "GIPS Aperitif" 15. April 2010 Referat von Stefan Illmer

GIPS 2010 Gesamtüberblick. Dr. Stefan J. Illmer Credit Suisse. Seminar der SBVg GIPS Aperitif 15. April 2010 Referat von Stefan Illmer GIPS 2010 Gesamtüberblick Dr. Stefan J. Illmer Credit Suisse Agenda Ein bisschen Historie - GIPS 2010 Fundamentals of Compliance Compliance Statement Seite 3 15.04.2010 Agenda Ein bisschen Historie - GIPS

Mehr

Support Technologies based on Bi-Modal Network Analysis. H. Ulrich Hoppe. Virtuelles Arbeiten und Lernen in projektartigen Netzwerken

Support Technologies based on Bi-Modal Network Analysis. H. Ulrich Hoppe. Virtuelles Arbeiten und Lernen in projektartigen Netzwerken Support Technologies based on Bi-Modal Network Analysis H. Agenda 1. Network analysis short introduction 2. Supporting the development of virtual organizations 3. Supporting the development of compentences

Mehr

An Introduction to Monetary Theory. Rudolf Peto

An Introduction to Monetary Theory. Rudolf Peto An Introduction to Monetary Theory Rudolf Peto 0 Copyright 2013 by Prof. Rudolf Peto, Bielefeld (Germany), www.peto-online.net 1 2 Preface This book is mainly a translation of the theoretical part of my

Mehr

Role Play I: Ms Minor Role Card. Ms Minor, accountant at BIGBOSS Inc.

Role Play I: Ms Minor Role Card. Ms Minor, accountant at BIGBOSS Inc. Role Play I: Ms Minor Role Card Conversation between Ms Boss, CEO of BIGBOSS Inc. and Ms Minor, accountant at BIGBOSS Inc. Ms Boss: Guten Morgen, Frau Minor! Guten Morgen, Herr Boss! Frau Minor, bald steht

Mehr

The impact of patient age on carotid atherosclerosis results from the Munich carotid biobank

The impact of patient age on carotid atherosclerosis results from the Munich carotid biobank Klinik und Poliklinik für Vaskuläre und Endovaskuläre Chirurgie Interdisziplinäres Gefäßzentrum Klinikum rechts der Isar (MRI) der TU München (TUM) Headline bearbeiten The impact of patient age on carotid

Mehr

Security Planning Basics

Security Planning Basics Einführung in die Wirtschaftsinformatik VO WS 2009/2010 Security Planning Basics Gerald.Quirchmayr@univie.ac.at Textbook used as basis for these slides and recommended as reading: Whitman, M. E. & Mattord,

Mehr

The Master of Science Entrepreneurship and SME Management

The Master of Science Entrepreneurship and SME Management The Master of Science Entrepreneurship and SME Management 1 WELCOME! 2 Our Business Faculty focus on SME and Innovation. We are accredited from AQAS. Thus, our Master in SME offers a new and innovative

Mehr

Bayerisches Landesamt für Statistik und Datenverarbeitung Rechenzentrum Süd. z/os Requirements 95. z/os Guide in Lahnstein 13.

Bayerisches Landesamt für Statistik und Datenverarbeitung Rechenzentrum Süd. z/os Requirements 95. z/os Guide in Lahnstein 13. z/os Requirements 95. z/os Guide in Lahnstein 13. März 2009 0 1) LOGROTATE in z/os USS 2) KERBEROS (KRB5) in DFS/SMB 3) GSE Requirements System 1 Requirement Details Description Benefit Time Limit Impact

Mehr

Modul Strategic Management (PGM-07)

Modul Strategic Management (PGM-07) Modul Strategic Management (PGM-07) Beschreibung u. Ziele des Moduls Dieses Modul stellt als eine der wesentlichen Formen wirtschaftlichen Denkens und Handelns den strategischen Ansatz vor. Es gibt einen

Mehr

REQUEST FOR YOUR MEDICAL SECOND OPINION REPORT ANTRAG AUF IHR MEDIZINISCHES ZWEITE MEINUNG - GUTACHTEN

REQUEST FOR YOUR MEDICAL SECOND OPINION REPORT ANTRAG AUF IHR MEDIZINISCHES ZWEITE MEINUNG - GUTACHTEN REQUEST FOR YOUR MEDICAL SECOND OPINION REPORT ANTRAG AUF IHR MEDIZINISCHES ZWEITE MEINUNG - GUTACHTEN SECOND OPINION REPORT ZWEITE MEINUNG GUTACHTEN netto Euro brutto Euro medical report of a medical

Mehr

Evidence of strobilurine resistant isolates of A. solani and A. alternata in Germany

Evidence of strobilurine resistant isolates of A. solani and A. alternata in Germany Technische Universität München Evidence of strobilurine resistant isolates of A. solani and A. alternata in Germany H. Hausladen, B. Adolf and J. Leiminger outline introduction material and methods results

Mehr

German hospital nurses attitudes concerning evidence-based nursing practice

German hospital nurses attitudes concerning evidence-based nursing practice German hospital nurses attitudes concerning evidence-based nursing practice Anja Behncke, Katrin Balzer, Sascha Köpke Evidence-based practice (EBP) Claim for EBP best research evidence patient values clinical

Mehr

Application Form ABOUT YOU INFORMATION ABOUT YOUR SCHOOL. - Please affix a photo of yourself here (with your name written on the back) -

Application Form ABOUT YOU INFORMATION ABOUT YOUR SCHOOL. - Please affix a photo of yourself here (with your name written on the back) - Application Form ABOUT YOU First name(s): Surname: Date of birth : Gender : M F Address : Street: Postcode / Town: Telephone number: Email: - Please affix a photo of yourself here (with your name written

Mehr

Frequently asked Questions for Kaercher Citrix (apps.kaercher.com)

Frequently asked Questions for Kaercher Citrix (apps.kaercher.com) Frequently asked Questions for Kaercher Citrix (apps.kaercher.com) Inhalt Content Citrix-Anmeldung Login to Citrix Was bedeutet PIN und Token (bei Anmeldungen aus dem Internet)? What does PIN and Token

Mehr

XV1100K(C)/XV1100SK(C)

XV1100K(C)/XV1100SK(C) Lexware Financial Office Premium Handwerk XV1100K(C)/XV1100SK(C) All rights reserverd. Any reprinting or unauthorized use wihout the written permission of Lexware Financial Office Premium Handwerk Corporation,

Mehr

Remission in Non-Operated Patients with Diffuse Disease and Long-Term Conservative Treatment.

Remission in Non-Operated Patients with Diffuse Disease and Long-Term Conservative Treatment. 5th Congenital Hyperinsulinism International Family Conference Milan, September 17-18 Remission in Non-Operated Patients with Diffuse Disease and Long-Term Conservative Treatment. PD Dr. Thomas Meissner

Mehr

Software development with continuous integration

Software development with continuous integration Software development with continuous integration (FESG/MPIfR) ettl@fs.wettzell.de (FESG) neidhardt@fs.wettzell.de 1 A critical view on scientific software Tendency to become complex and unstructured Highly

Mehr

-Which word (lines 47-52) does tell us that Renia s host brother is a pleasant person?

-Which word (lines 47-52) does tell us that Renia s host brother is a pleasant person? Reading tasks passend zu: Open World 1 Unit 4 (student s book) Through a telescope (p. 26/27): -Renia s exchange trip: richtig falsch unkar? richtig falsch unklar: Renia hat sprachliche Verständnisprobleme.

Mehr

RailMaster New Version 7.00.p26.01 / 01.08.2014

RailMaster New Version 7.00.p26.01 / 01.08.2014 RailMaster New Version 7.00.p26.01 / 01.08.2014 English Version Bahnbuchungen so einfach und effizient wie noch nie! Copyright Copyright 2014 Travelport und/oder Tochtergesellschaften. Alle Rechte vorbehalten.

Mehr

In vier Schritten zum Titel. erfolgreichen Messeauftritt. Four steps to a successful trade fair. Hier beginnt Zukunft! The future starts here!

In vier Schritten zum Titel. erfolgreichen Messeauftritt. Four steps to a successful trade fair. Hier beginnt Zukunft! The future starts here! In vier Schritten zum Titel erfolgreichen Messeauftritt. Four steps to a successful trade fair. Hier beginnt Zukunft! The future starts here! Einleitung Intro Um Sie dabei zu unterstützen, Ihren Messeauftritt

Mehr

Zugangsvoraussetzungen für Airworthiness Review Staff gem. Part-M.A.707

Zugangsvoraussetzungen für Airworthiness Review Staff gem. Part-M.A.707 1) Zusammenfassung der relevanten Part-M Paragraphen und AMC M.A.707 Airworthiness review staff (a) To be approved to carry out reviews, an approved continuing management organisation shall have appropriate

Mehr

Heisenberg meets reading

Heisenberg meets reading Heisenberg meets reading Gregory Crane Professor of Classics Winnick Family Chair of Technology and Entrepreneurship Adjunct Professor of Computer Science Editor in Chief, Perseus Project January 12, 2013

Mehr

MEETING FRIENDS M.A.S.T.E.R.-Conference International Members Meeting & Training Courses. M.A.S.T.E.R. Conference. Berlin, September 12 & 13

MEETING FRIENDS M.A.S.T.E.R.-Conference International Members Meeting & Training Courses. M.A.S.T.E.R. Conference. Berlin, September 12 & 13 M.A.S.T.E.R. Conference International Members Meeting NETWORK-Lipolysis & NETWORK-Globalhealth MEETING FRIENDS M.A.S.T.E.R.-Conference International Members Meeting & Training Courses Berlin, September

Mehr

Total Security Intelligence. Die nächste Generation von Log Management and SIEM. Markus Auer Sales Director Q1 Labs.

Total Security Intelligence. Die nächste Generation von Log Management and SIEM. Markus Auer Sales Director Q1 Labs. Total Security Intelligence Die nächste Generation von Log Management and SIEM Markus Auer Sales Director Q1 Labs IBM Deutschland 1 2012 IBM Corporation Gezielte Angriffe auf Unternehmen und Regierungen

Mehr

Englisch. Schreiben. 18. September 2015 HTL. Standardisierte kompetenzorientierte schriftliche Reife- und Diplomprüfung. Name: Klasse/Jahrgang:

Englisch. Schreiben. 18. September 2015 HTL. Standardisierte kompetenzorientierte schriftliche Reife- und Diplomprüfung. Name: Klasse/Jahrgang: Name: Klasse/Jahrgang: Standardisierte kompetenzorientierte schriftliche Reife- und Diplomprüfung HTL 18. September 2015 Englisch (B2) Schreiben Hinweise zum Beantworten der Fragen Sehr geehrte Kandidatin,

Mehr

Autologe und allogene Stammzelltransplantation beim Multiplen Myelom. Sandra Sauer / Ute Hegenbart Medizinische Klinik V Universität t Heidelberg

Autologe und allogene Stammzelltransplantation beim Multiplen Myelom. Sandra Sauer / Ute Hegenbart Medizinische Klinik V Universität t Heidelberg Autologe und allogene Stammzelltransplantation beim Multiplen Myelom Sandra Sauer / Ute Hegenbart Medizinische Klinik V Universität t Heidelberg Entwicklung der Therapien beim Multiplen Myelom Hoch-Dosis

Mehr

Medienorientierung: Eckenstein-Geigy Professur für Pädiatrische Pharmakologie

Medienorientierung: Eckenstein-Geigy Professur für Pädiatrische Pharmakologie Medienorientierung: Eckenstein-Geigy Professur für Pädiatrische Pharmakologie Mittwoch, 25. Juni 2014 Bibliothek UKBB (4. OG), Spitalstrasse 33, Basel Programm 10.00 Uhr Begrüssung Dr. med. Conrad E. Müller,

Mehr

Best Practise in England. Osnabrücker Baubetriebstage 2012. Yvette Etcell LLB Business Development & HR

Best Practise in England. Osnabrücker Baubetriebstage 2012. Yvette Etcell LLB Business Development & HR Hochschule Osnabrück University of Applied Sciences Investors in People Best Practise in England Yvette Etcell LLB Business Development & HR Gavin Jones Ltd., UK Osnabrücker Baubetriebstage 2012 Die Seminarunterlagen

Mehr

Your Partner for Luxury and Lifestyle Estates Ihr Partner für Luxus- und Lifestyle-Immobilien

Your Partner for Luxury and Lifestyle Estates Ihr Partner für Luxus- und Lifestyle-Immobilien Your Partner for Luxury and Lifestyle Estates Ihr Partner für Luxus- und Lifestyle-Immobilien Welcome to Premier Suisse Estates Willkommen bei Premier Suisse Estates Dr. Peter Moertl, CEO Premier Suisse

Mehr

Mash-Up Personal Learning Environments. Dr. Hendrik Drachsler

Mash-Up Personal Learning Environments. Dr. Hendrik Drachsler Decision Support for Learners in Mash-Up Personal Learning Environments Dr. Hendrik Drachsler Personal Nowadays Environments Blog Reader More Information Providers Social Bookmarking Various Communities

Mehr

«Zukunft Bildung Schweiz»

«Zukunft Bildung Schweiz» «Zukunft Bildung Schweiz» Von der Selektion zur Integration Welche Art von Schule wirkt sich positiv auf eine «gute» zukünftige Gesellschaft aus? Eine Schwedische Perspektive. Bern 16-17.06.2011 Referent:

Mehr

Staatenübergreifende Ärzteausbildung Peter Dieter President of AMSE (Association of Medical Schools in Europe)

Staatenübergreifende Ärzteausbildung Peter Dieter President of AMSE (Association of Medical Schools in Europe) Staatenübergreifende Ärzteausbildung Peter Dieter President of AMSE (Association of Medical Schools in Europe) Peter Dieter, 20. Juni 2014, omft, Frankfurt 1 AMSE Association of Medical Schools in Europe

Mehr

IMRF-Crew-Exchange-Program 2014: Sei dabei... 27. September bis 04. Oktober 2014

IMRF-Crew-Exchange-Program 2014: Sei dabei... 27. September bis 04. Oktober 2014 IMRF-Crew-Exchange-Program 2014: Sei dabei... Sei dabei... 27. September bis 04. Oktober 2014 So werben wir in der Öffentlichkeit um Neugier, Interesse und Zusammengehörigkeit! Kolleginnen und Kollegen:

Mehr

Want to have more impressions on our daily activities? Just visit our facebook homepage:

Want to have more impressions on our daily activities? Just visit our facebook homepage: Dear parents, globegarden friends and interested readers, We are glad to share our activities from last month and wish you lots of fun while looking at all we have been doing! Your team from globegarden

Mehr

Dossier AD586. Limited edition

Dossier AD586. Limited edition Dossier AD586 Market study of Holst Porzellan GmbH regarding the online trading volume of European manufacturers from 15.08.2012 until 29.08.2012 on the Internet platform ebay in the Federal Republic of

Mehr

KURZANLEITUNG. Firmware-Upgrade: Wie geht das eigentlich?

KURZANLEITUNG. Firmware-Upgrade: Wie geht das eigentlich? KURZANLEITUNG Firmware-Upgrade: Wie geht das eigentlich? Die Firmware ist eine Software, die auf der IP-Kamera installiert ist und alle Funktionen des Gerätes steuert. Nach dem Firmware-Update stehen Ihnen

Mehr

MUSKEL LEISTUNGSDIAGNOSE

MUSKEL LEISTUNGSDIAGNOSE MUSKEL LEISTUNGSDIAGNOSE 1 MUSKELLEISTUNGSDIAGNOSE 2 MusclePerformanceDiagnosis measure - diagnose optimize performance Motorleistung PS Muskelleistung W/kg 3 Performance development Create an individual

Mehr

Act on Human Genetic Testing (Genetic Diagnosis Act; GenDG)

Act on Human Genetic Testing (Genetic Diagnosis Act; GenDG) Legal provisions related to genetic testing in Germany Act on Human Genetic Testing (Genetic Diagnosis Act; GenDG) Holger Tönnies Robert Koch-Institut Genetic Diagnostic Commission Head of Office European

Mehr

DAS METABOLOM: ERNÄHRUNGSSTATUS, METABOLISMUS, METABOLITEN

DAS METABOLOM: ERNÄHRUNGSSTATUS, METABOLISMUS, METABOLITEN DAS METABOLOM: ERNÄHRUNGSSTATUS, METABOLISMUS, METABOLITEN Das Metabolom Extrinsiche Faktoren Ernährung (Nährstoffe und nicht nutritive Lebensmittelinhaltsstoffe) Arzneimittel Physische Aktivität Darmflora

Mehr

AS Path-Prepending in the Internet And Its Impact on Routing Decisions

AS Path-Prepending in the Internet And Its Impact on Routing Decisions (SEP) Its Impact on Routing Decisions Zhi Qi ytqz@mytum.de Advisor: Wolfgang Mühlbauer Lehrstuhl für Netzwerkarchitekturen Background Motivation BGP -> core routing protocol BGP relies on policy routing

Mehr

Accounting course program for master students. Institute of Accounting and Auditing http://www.wiwi.hu-berlin.de/rewe

Accounting course program for master students. Institute of Accounting and Auditing http://www.wiwi.hu-berlin.de/rewe Accounting course program for master students Institute of Accounting and Auditing http://www.wiwi.hu-berlin.de/rewe 2 Accounting requires institutional knowledge... 3...but it pays: Lehman Bros. Inc.,

Mehr

Porsche Consulting. Operational excellence successful processes from the automotive industry and their applications in medical technology

Porsche Consulting. Operational excellence successful processes from the automotive industry and their applications in medical technology Porsche Consulting Operational excellence successful processes from the automotive industry and their applications in medical technology Especially crucial in medical technology: a healthy company. Germany

Mehr

Einkommensaufbau mit FFI:

Einkommensaufbau mit FFI: For English Explanation, go to page 4. Einkommensaufbau mit FFI: 1) Binäre Cycle: Eine Position ist wie ein Business-Center. Ihr Business-Center hat zwei Teams. Jedes mal, wenn eines der Teams 300 Punkte

Mehr

ReadMe zur Installation der BRICKware for Windows, Version 6.1.2. ReadMe on Installing BRICKware for Windows, Version 6.1.2

ReadMe zur Installation der BRICKware for Windows, Version 6.1.2. ReadMe on Installing BRICKware for Windows, Version 6.1.2 ReadMe zur Installation der BRICKware for Windows, Version 6.1.2 Seiten 2-4 ReadMe on Installing BRICKware for Windows, Version 6.1.2 Pages 5/6 BRICKware for Windows ReadMe 1 1 BRICKware for Windows, Version

Mehr

E-Discovery the EU Data Protection Authorities approach

E-Discovery the EU Data Protection Authorities approach E-Discovery the EU Data Protection Authorities approach Breakout Session Mind the Gap: Bridging U.S. Cross-border E-discovery and EU Data Protection Obligations Dr. Alexander Dix, LL.M. Berlin Commissioner

Mehr

XML Template Transfer Transfer project templates easily between systems

XML Template Transfer Transfer project templates easily between systems Transfer project templates easily between systems A PLM Consulting Solution Public The consulting solution XML Template Transfer enables you to easily reuse existing project templates in different PPM

Mehr

Using TerraSAR-X data for mapping of damages in forests caused by the pine sawfly (Dprion pini) Dr. Klaus MARTIN klaus.martin@slu-web.

Using TerraSAR-X data for mapping of damages in forests caused by the pine sawfly (Dprion pini) Dr. Klaus MARTIN klaus.martin@slu-web. Using TerraSAR-X data for mapping of damages in forests caused by the pine sawfly (Dprion pini) Dr. Klaus MARTIN klaus.martin@slu-web.de Damages caused by Diprion pini Endangered Pine Regions in Germany

Mehr

Long-term archiving of medical data new certified cloud-based solution offers high security and legally approved data management

Long-term archiving of medical data new certified cloud-based solution offers high security and legally approved data management Long-term archiving of medical data new certified cloud-based solution offers high security and legally approved data management The European Centre of Expertise for the Health Care Industry Langzeitarchivierung

Mehr

Introduction Classified Ad Models Capital Markets Day Berlin, December 10, 2014. Dr Andreas Wiele, President Marketing and Classified Ad Models

Introduction Classified Ad Models Capital Markets Day Berlin, December 10, 2014. Dr Andreas Wiele, President Marketing and Classified Ad Models Capital Markets Day Berlin, December 10, 2014 Dr Andreas Wiele, President Marketing and Classified Ad Models Axel Springer s transformation to digital along core areas of expertise 3 Zimmer mit Haus im

Mehr

Delivering services in a user-focussed way - The new DFN-CERT Portal -

Delivering services in a user-focussed way - The new DFN-CERT Portal - Delivering services in a user-focussed way - The new DFN-CERT Portal - 29th TF-CSIRT Meeting in Hamburg 25. January 2010 Marcus Pattloch (cert@dfn.de) How do we deal with the ever growing workload? 29th

Mehr

Effective Stakeholder Management at the Technische Universität München Bologna, September, 2010

Effective Stakeholder Management at the Technische Universität München Bologna, September, 2010 Effective Stakeholder Management at the Bologna, September, 2010 Science, Technology, and the Media Growing public awareness for the last 10 years New print and web journals Large number of new TV shows

Mehr

3. BvD Transfer Pricing Day BEPS und die Auswirkungen auf das operationale Verrechnungspreis-Management

3. BvD Transfer Pricing Day BEPS und die Auswirkungen auf das operationale Verrechnungspreis-Management 3. BvD Transfer Pricing Day BEPS und die Auswirkungen auf das operationale Verrechnungspreis-Management Agenda Einführung Operationales Verrechnungspreis- Management Was bedeutet BEPS für Unternehmen?

Mehr

Fluid-Particle Multiphase Flow Simulations for the Study of Sand Infiltration into Immobile Gravel-Beds

Fluid-Particle Multiphase Flow Simulations for the Study of Sand Infiltration into Immobile Gravel-Beds 3rd JUQUEEN Porting and Tuning Workshop Jülich, 2-4 February 2015 Fluid-Particle Multiphase Flow Simulations for the Study of Sand Infiltration into Immobile Gravel-Beds Tobias Schruff, Roy M. Frings,

Mehr

Versicherungsschutz. sicher reisen weltweit!

Versicherungsschutz. sicher reisen weltweit! I N F O R M A T I O N E N Z U d einem Versicherungsschutz im au s l an d R ei s e v er s i c h erun g s s c h utz sicher reisen weltweit! RD 281_0410_Eurovacances_BB.indd 1 14.06.2010 11:26:22 Uhr Please

Mehr

Bewertungsbogen. Please find the English version of the evaluation form at the back of this form

Bewertungsbogen. Please find the English version of the evaluation form at the back of this form Bewertungsbogen Please find the English version of the evaluation form at the back of this form Vielen Dank für Ihre Teilnahme an der BAI AIC 2015! Wir sind ständig bemüht, unsere Konferenzreihe zu verbessern

Mehr

CUSTOMER INFORMATION 2014-08-21

CUSTOMER INFORMATION 2014-08-21 CUSTOMER INFORMATION 2014-08-21 Introduction of Inter-Product-Spreads as part of the T7 Release 2.5 Dear Trading Participants, With this customer information EEX Power Derivatives would like to inform

Mehr

Part I Learning Agreement for Studies Academic Year 2015/16

Part I Learning Agreement for Studies Academic Year 2015/16 Part I Learning Agreement for Studies Academic Year 2015/16 Bitte beachten Sie auch die Ausfüllhilfe auf der letzten Seite. The Student Last name(s): First name(s): Date of birth: Nationality: Sex: Phone:

Mehr

Zentrale Auslands- und Fachvermittlung (ZAV) Skilled and academic workforce for Germany Your Partner, the ZAV

Zentrale Auslands- und Fachvermittlung (ZAV) Skilled and academic workforce for Germany Your Partner, the ZAV Zentrale Auslands- und Fachvermittlung (ZAV) Ralf Czadzeck Offenbach, March 13th.,2012 Skilled and academic workforce for Germany Your Partner, the ZAV Qualified workforce from abroad How ZAV can support

Mehr

H. Enke, Sprecher des AK Forschungsdaten der WGL

H. Enke, Sprecher des AK Forschungsdaten der WGL https://escience.aip.de/ak-forschungsdaten H. Enke, Sprecher des AK Forschungsdaten der WGL 20.01.2015 / Forschungsdaten - DataCite Workshop 1 AK Forschungsdaten der WGL 2009 gegründet - Arbeit für die

Mehr

slides alcohol prk.wmv

slides alcohol prk.wmv Pain and functioning post Alcohol PRK vs. -PRK: A prospective Intra-individual Comparison Toam Katz, Gisbert Richard, S. J. Linke Subjektive Entwicklung der Schmerzsymptomatik und Funktion nach Alcohol

Mehr